PARP1 and anemia: In terms of AEs, the use of PARP inhibitors did not significantly increase the overall risk of AEs (RR = 1.04, p=0.16), but in specific AEs, anemia and thrombocytopenia were the most common AEs, and their risk values were 3.40 (95% CI 1.86–6.19, p < 0.001) for anemia and 3.59 (95% CI 1.65–7.78, p < 0.001) for thrombocytopenia.